During the seminar, Fan shared insights into the changing dynamics of China’s innovative drug BD market and the growing opportunities for cross-border collaboration. As China continues to play an increasingly important role in the global life sciences ecosystem, understanding the local market landscape and evolving transaction environment has become increasingly important for international pharmaceutical and biotechnology companies seeking strategic partnerships.

The seminar covered three key areas:

• China BD Trends and Market Opportunities: An overview of the evolving China life sciences and innovative drug BD landscape, as well as the opportunities available for companies seeking partnerships and collaboration in China.
• China BD Transaction and Deal Structures: Insights into common transaction approaches and deal structures in China, helping companies better understand how partnerships can be structured to align the interests of different stakeholders.
• Key Considerations for Korean Companies: Practical considerations for Korean pharmaceutical and biotechnology companies exploring business development opportunities in China and global markets, including market understanding, partner identification, and transaction structuring.

For companies seeking to expand into China or pursue global partnering opportunities, successful cross-border business development requires more than identifying attractive market opportunities. Understanding the market, identifying the right strategic partners, and developing an appropriate deal structure are all critical elements in building successful and sustainable collaborations.

YAFO Capital supports life sciences companies throughout this process by providing systematic China/APAC and global BD advisory support. Established in 2013, YAFO Capital is a boutique advisory firm helping clients navigate cross-border partnering opportunities—from market and opportunity assessment, partner identification, and outreach to negotiation and deal closing.

The seminar also highlighted the growing potential for collaboration between the Chinese and Korean life sciences industries. With both markets continuing to develop strong pharmaceutical and biotechnology capabilities, cross-border partnerships can create new opportunities for innovation, technology development, and global market expansion.

YAFO Capital would like to thank the CPHI Korea team, the Korea Institute of Toxicology, and all participants who joined the session and contributed to the discussion.

YAFO Capital looks forward to continuing to support stronger China–Korea life sciences partnerships and helping pharmaceutical and biotechnology companies navigate business development opportunities across China, the Asia-Pacific region, and global markets.

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., EU, and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong, proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions.  For more information, please visit http://www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。

 Contact us:

Headquarter office
Room 1201, 958 Lujiazui Ring Road, Pudong New Area, Shanghai, China
wxiang@yafocapital.com